Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CEO David P. Schenkein sold 6,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $66.76, for a total value of $400,560.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Agios Pharmaceuticals, Inc. (AGIO) traded up 1.39% during mid-day trading on Wednesday, hitting $70.25. The stock had a trading volume of 1,017,271 shares. The firm’s market cap is $3.40 billion. Agios Pharmaceuticals, Inc. has a 52 week low of $39.24 and a 52 week high of $71.40. The company’s 50 day moving average price is $62.68 and its 200 day moving average price is $55.80.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by ($0.21). Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The company had revenue of $11.30 million for the quarter, compared to the consensus estimate of $10.68 million. During the same quarter in the previous year, the business earned ($1.47) earnings per share. Agios Pharmaceuticals’s revenue was up 62.1% compared to the same quarter last year. Analysts anticipate that Agios Pharmaceuticals, Inc. will post ($7.07) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/10/04/insider-selling-agios-pharmaceuticals-inc-agio-ceo-sells-6000-shares-of-stock.html.

A number of institutional investors and hedge funds have recently bought and sold shares of AGIO. BlackRock Inc. grew its position in Agios Pharmaceuticals by 8,463.5% during the 1st quarter. BlackRock Inc. now owns 2,167,074 shares of the biopharmaceutical company’s stock worth $126,556,000 after acquiring an additional 2,141,768 shares during the last quarter. FMR LLC grew its position in Agios Pharmaceuticals by 14.1% during the 2nd quarter. FMR LLC now owns 7,227,331 shares of the biopharmaceutical company’s stock worth $371,846,000 after acquiring an additional 895,584 shares during the last quarter. Vanguard Group Inc. grew its position in Agios Pharmaceuticals by 23.8% during the 2nd quarter. Vanguard Group Inc. now owns 3,214,770 shares of the biopharmaceutical company’s stock worth $165,401,000 after acquiring an additional 617,379 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Agios Pharmaceuticals by 748.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 649,124 shares of the biopharmaceutical company’s stock worth $37,909,000 after acquiring an additional 572,579 shares during the last quarter. Finally, Janus Henderson Group PLC bought a new position in Agios Pharmaceuticals during the 2nd quarter worth approximately $20,423,000. Institutional investors and hedge funds own 94.40% of the company’s stock.

A number of research analysts have issued reports on the company. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $80.00 target price on shares of Agios Pharmaceuticals in a research report on Wednesday. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $83.00 target price (up previously from $75.00) on shares of Agios Pharmaceuticals in a research report on Thursday, August 10th. J P Morgan Chase & Co reiterated a “buy” rating and issued a $76.00 target price on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. Royal Bank Of Canada assumed coverage on Agios Pharmaceuticals in a research report on Thursday, September 14th. They issued an “outperform” rating and a $78.00 target price on the stock. Finally, Cann reiterated a “buy” rating and issued a $75.00 target price on shares of Agios Pharmaceuticals in a research report on Sunday, June 11th. Four investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Agios Pharmaceuticals has an average rating of “Buy” and an average price target of $75.20.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.